Diagnosing Pancreatic Acinar Cell Carcinoma: An Integrative Detective Story

Diagnosing pancreatic acinar cell carcinoma (ACC) is less a linear clinical pathway and more a complex detective story. The initial clues are often frustratingly vague—abdominal pain, weight loss, or occasionally, a distinctive paraneoplastic syndrome characterized by polyarthralgia and eosinophilia due to excess lipase secretion. The “crime scene” is the pancreas, deep within the abdomen, and the “culprit” is a rare and cunning chameleon of a tumor. To solve this case, modern medicine has assembled a multi-disciplinary task force, moving beyond a single diagnostic test to an integrative approach that synthesizes radiology, histopathology, and molecular genetics to not only identify the tumor but also to immediately profile its vulnerabilities.

The first lead in the investigation comes from advanced imaging. A multiphase contrast-enhanced CT scan or MRI is the initial canvassing tool. Unlike PDAC, which typically presents as a poorly defined, hypovascular mass causing ductal obstruction, ACC often appears as a larger, well-circumscribed, and sometimes exophytic lesion. It may be hypervascular, a subtle clue that can raise suspicion for a non-ductal neoplasm. However, imaging alone cannot make the definitive diagnosis. It can only suggest that the usual suspect (PDAC) might not be the culprit. For a closer look, the investigative team calls in its specialist: Endoscopic Ultrasound (EUS). EUS provides high-resolution, real-time visualization of the lesion and, crucially, enables the next critical step in the investigation: acquiring tissue evidence.tissue array

The definitive identification of ACC rests on the pathological examination of a specimen obtained via EUS-guided fine-needle aspiration (FNA). This is where the case is cracked, but not with a simple microscope. The detective work here involves a sophisticated technique called immunohistochemistry (IHC). A pathologist applies a panel of stains to the tissue cells, looking for specific protein markers that act like a molecular fingerprint. For ACC, the fingerprint is the strong, diffuse expression of acinar cell differentiation markers such as trypsin, chymotrypsin, lipase, and BCL10. The presence of these markers confirms the tumor’s origin from the pancreatic acinar cells, decisively ruling out more common impostors like PDAC (which is positive for CK7 and CK19) and pancreatic neuroendocrine tumors (which are positive for chromogranin and synaptophysin). This step is non-negotiable; without IHC, the diagnosis remains speculative.

But the modern diagnostic story doesn’t end with a simple identification. In a paradigm shift, the final and most forward-thinking step is molecular interrogation of the same tissue sample. Sending the FNA specimen for next-generation sequencing (NGS) is no longer a research-only endeavor; it is becoming a standard part of the initial diagnostic workup for suspected ACC. This is the moment when diagnosis and treatment planning converge. The NGS report acts as an intelligence dossier, revealing the tumor’s actionable weaknesses. It can confirm the diagnosis by finding genomic alterations common in ACC (like *BRAF* or *RELA* fusions) and, more importantly, identify targets for therapy—such as *BRAF V600E* for BRAF inhibitors, *HRD* for PARP inhibitors, or *MSI-H* for immunotherapy. This molecular layer transforms the diagnosis from a static label into a dynamic, actionable blueprint.

Looking ahead, the diagnostic toolkit is poised to expand with the advent of liquid biopsies. While still primarily a tool for monitoring, the potential to use circulating tumor DNA (ctDNA) for initial diagnosis, especially in cases where tissue biopsy is risky or inconclusive, is on the horizon. This would be the equivalent of solving the case from a single strand of hair left at the scene. In conclusion, diagnosing pancreatic acinar cell carcinoma today is an exercise in integrative detective work. It requires the radiologist’s eye, the pathologist’s precision, and the molecular geneticist’s insight to piece together a complete picture. This multi-modal approach ensures that by the time the verdict of “ACC” is delivered, the strategy for its prosecution is already in hand.